Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2024

Nasser Ali M, Melamed Lisa, Wetzel Ethan A, Chang Jenny Chia-Chen, Nagashima Hiroaki, Kitagawa Yosuke, Muzyka Logan, Wakimoto Hiroaki, Cahill Daniel P, Miller Julie J

Abstract excerpt

PURPOSE: Treatment paradigms for isocitrate dehydrogenase (IDH)-mutant gliomas are rapidly evolving. Although typically indolent and responsive to initial treatment, these tumors invariably recur at a higher grade and require salvage treatment. Homozygous deletion of the tumor suppressor gene CDKN2A/B frequently emerges at recurrence in these tumors, driving poor patient outcomes. We investigated the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Cyclin-Dependent Kinase Inhibitor p15

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Piperazines

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 38718141
DOI: 10.1158/1078-0432.CCR-24-0562
PMCID: PMC11250907

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.PMID 38718141Read ↗

Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture modelsSemantic proximity Read ↗

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Semantic proximity Read ↗

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell culturesSemantic proximity Read ↗

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in <i>IDH1</i> -mutant gliomaSemantic proximity Read ↗

Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclibSemantic proximity Read ↗

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.Semantic proximity Read ↗

A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.Semantic proximity Read ↗

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Semantic proximity Read ↗

Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.Semantic proximity Read ↗

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.Semantic proximity Read ↗

The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assaysSemantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.